Antithrombotic therapy for stroke prevention in patients with atrial fibrillation who survive an intracerebral haemorrhage: results of an EHRA survey

Elena Ivany1,†, Deirdre A. Lane1,2,†, Gheorghe-Andrei Dan3, Wolfram Doehner4,5,6,7, Michal M. Farkowski8, Konstantinos Iliodromitis9, Radoslaw Lenarczyk10, and Tatjana S. Potpara11,12

1Liverpool Centre for Cardiovascular Science, University of Liverpool, 6 West Derby Street, Liverpool L7 8TX, UK; 2Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; 3Internal Medicine, Carol Davila University of Medicine, Colentina University Hospital, Bucharest, Romania; 4Berlin Institute of Health Center for Regenerative Therapies, Berlin, Germany; 5Department of Cardiology (Virchow Klinikum), Charité – Universitätsmedizin Berlin, Berlin, Germany; 6German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany; 7Center for Stroke Research Berlin, Charité – Universitätsmedizin Berlin, Berlin, Germany; 8II Department of Heart Arrhythmia, National Institute of Cardiology, Warsaw, Poland; 9Clinic for Cardiology and Electrophysiology, Evangelisches Krankenhaus Hagen-Hapke, Hagen, Germany; 10Department of Cardiology, Congenital Heart Defects and Electrophysiology, Medical University of Silesia, Silesian Center of Heart Disease, Zabrze, Poland; 11Serbia School of Medicine, University of Belgrade, Belgrade, Serbia; and 12Department for Intensive Care in Cardiac Arrhythmia, Cardiology Clinic, Clinical Centre of Serbia, Belgrade, Serbia

Received 30 November 2020; editorial decision 20 December 2020; accepted after revision 30 December 2020

The aim of this survey is to provide a snapshot of current practice regarding antithrombotic therapy (ATT) in patients with atrial fibrillation (AF) comorbid with intracerebral haemorrhage (ICH). An online survey was distributed to members of the European Heart Rhythm Association. A total of 163 clinicians responded, mostly cardiologists or electrophysiologists (87.7%), predominantly working in University hospitals (61.3%). Most respondents (47.2%) had seen one to five patients with AF comorbid with ICH in the last 12 months. Among patients sustaining an ICH on oral anticoagulation (OAC), 84.3% respondents would consider some form of ATT post-ICH, with 73.2% preferring to switch from a vitamin-K antagonist (VKA) to a non-VKA oral anticoagulant (NOAC) and 37.2% preferring to switch from one NOAC to another. Most (36.6%) would restart OAC >30 days post-ICH. Among patients considered unable to take OAC, left atrial appendage occlusion procedure was the therapy of choice in 73.3% respondents. When deciding on ATT, respondents considered patient’s CHA2DS2-VASc score, ICH type, demographics, risk factors, and patient adherence. The main reason for not restarting or commencing ATT was concern about recurrent ICH (80.8%). National or international clinical guidelines would be advantageous to support decision-making (84.3%). Other helpful resources reported were multidisciplinary team involvement (46.9%) and patient education (82%).

In summary, most survey respondents would prescribe OAC therapy for patients with AF who have sustained an ICH on OAC and would restart OAC >30 days post-ICH. The risk of recurrent ICH was the main reason for not prescribing any ATT post-ICH.

Keywords

Atrial fibrillation • Intracerebral haemorrhage • Anticoagulation • Non-vitamin K antagonist oral anticoagulants • Vitamin K antagonist • EHRA survey

Introduction

Atrial fibrillation (AF) is associated with a five-fold increased risk of ischaemic stroke1 and as a result, long-term oral anticoagulation (OAC) is the cornerstone of AF treatment for the majority of patients.2 However, OAC treatment is associated with an increased risk of bleeding, where intracerebral haemorrhage (ICH) is the most feared haemorrhagic complication due to its increased risk of death (36% at 1 month) and significant morbidity.3 Over 10% of ICH is OAC related,4 although it may also be the case that OAC acts as a catalyst for the ICH process.
rather than as a direct cause. It is estimated that up to 30% of patients with ICH also have AF. All types of antithrombotic therapy (ATT) are associated with increased bleeding risk, although non-vitamin-K antagonist oral anticoagulants (NOAC) are associated with a reduced risk of intracranial haemorrhage in AF patients compared with warfarin [Relative risk (RR) 0.49 (95% 0.38–0.64, \(P < 0.0001\)].

A dilemma for clinicians and patients is the initiation of ATT for ischaemic stroke prevention in patients who have AF and have also sustained an ICH. Patients with ICH were excluded from seminal trials on NOAC but data from observational studies seem to suggest that restarting OAC post-ICH in patients with known AF reduces the risk of ischaemic stroke without significantly increasing the risk of repeat ICH. However, there are currently no definitive data from randomized controlled trials (RCT) that address OAC treatment in the AF and ICH patient population, although several trials are ongoing (NCT02565693, NCT03907046, NCT03996772, NCT02998905, NCT03186729, and NCT03186729).

The aim of this European Heart Rhythm Association (EHRA) survey was to assess current practice regarding ATT in patients who have AF and who have also sustained an ICH. This survey explored how physicians decide on ATT for this patient population by addressing issues such as timing of restarting or initiating ATT, first choice of ATT, and clinical factors that influence physicians’ decision-making on ATT post-ICH.

### Methods and results

The EHRA network was utilized to distribute an on-line questionnaire of 18 questions and five scenario-based questions (Box 1), between 18 August and 17 September 2020. A total of 163 physicians responded to the survey. Most respondents were based in Western Europe, although 73/163 (45%) clinicians from Asia Pacific, the Middle East, Africa, and the Americas also participated. Most respondents were cardiologists (88/163, 54%) or electrophysiologists (55/163, 33.7%) and worked at a University hospital (100/163, 61.3%) and in hospitals with a stroke unit (118/163, 72.4%).

Most respondents had encountered 1–5 patients with AF and ICH in the last 12 months (77/163, 47.2%), although 11/163 (6.7%) respondents had encountered >20 patients with AF and ICH in the last year.

### Factors considered when restarting or commencing antithrombotic therapy in patients with atrial fibrillation and an intracerebral haemorrhage

Patient’s CHA2DS2-VASc score was the main consideration (143/149, 96%) in ATT decision-making (Figure 1), followed by ICH aetiology (traumatic vs. spontaneous, 140/146, 95.9%), ICH severity (139/150, 92.7%), ICH type (124/141, 88%), and ICH volume/size (120/142, 84.5%). Risk of bleeding (HAS-BLED score) was selected as a consideration when deciding whether to restart or commence ATT by 127/151 (84.1%) respondents. Patient demographics and medical history were also important considerations for most participants. Patient age was a consideration for 119/141 (84.4%) participants, along with severity of uncontrolled hypertension (124/140, 88.6%), patient’s functional (119/136, 87.5%) and neurological status (116/137, 84.7%), and alcohol intake (106/138, 76.8%). Nearly all respondents (140/146, 95.9%) stated that patient adherence to medication was a consideration when deciding whether to commence or restart ATT.

Multidisciplinary team input (133/142, 93.7%) and patient preference (120/138, 87%) were considered more important in the decision-making process than individual clinician preference (85/131, 64.9%).

Respondents also had the option of adding their own individual considerations; three would consider the possibility of a left atrial appendage occlusion (LAAO) procedure. Echocardiography data were considered by two respondents, with drug cost, patient’s lifestyle, and patient proximity to the hospital, considered by one respondent each.

### Factors influencing physicians’ decision to restart or commence antithrombotic therapy in patients with atrial fibrillation who sustained an intracerebral haemorrhage while on oral anticoagulation

The type of OAC prescribed to the patient pre-ICH was the most influential factor (125/146, 85.6%) in the decision to restart or commence ATT post-ICH sustained on OAC (Figure 2), followed by patient-related factors, such as adherence (113/146, 77.4%), age (111/146, 76%), and history of falls (78/146, 53.4%). Individual stroke (CHA2DS2-VASc score, 110/146, 75.3%) and bleeding risk (HAS-BLED score, 108/146, 74%) was selected by about three-quarters of respondents as important factors in ATT decision-making. More than half of participants took into consideration previous quality of VKA control (such as time in therapeutic range, 96/146, 65.7%).

Additional factors influencing whether or not to prescribe ATT for a patient with AF who sustained an ICH while on OAC reported in free-text responses were patient’s lifestyle (n = 1), high cardioembolic risk and high cerebral haemorrhagic risk, such as cerebral
amyloid angiopathy (CAA) (n = 1), and feasibility of an LAAO procedure (n = 1).

**Choice of oral anticoagulation therapy to restart post-intracerebral haemorrhage**

The first-choice ATT among patients who had an ICH on OAC differed slightly depending on whether the patient was previously receiving a VKA or a NOAC (Figure 3). Overall, the preferred OAC was apixaban. A minority of respondents (15/153, 9.8%) said that they would restart the patient’s previous OAC (Figure 4). If the patient sustained an ICH while on NOAC, 57/153 (37.2%) of respondents said that they would switch the patient from one type of NOAC to another NOAC. A decision not to restart any type of OAC was only chosen by 24/153 (15.7%) respondents.

If the patient sustained an ICH while on NOAC, 57/153 (37.2%) respondents would switch the patient from one NOAC to another NOAC. For those who experienced an ICH on a NOAC, the preferred NOAC when restarting was apixaban (72/153, 47.1%), followed by dabigatran (20/153, 13.1%), rivaroxaban (12/153, 7.8%),...
and edoxaban (10/153, 6.5%). A VKA was selected by 10/153 respondents, with 8/153 (5.2%) choosing VKA with international normalized ratio (INR) 2.0–2.5 and 2/153 (1.3%) choosing VKA with INR 2.0–3.0. Antiplatelets were not a popular choice amongst respondents; only 4/153 (2.6%) respondents selected clopidogrel over other types of ATT, 3/153 (2%) chose aspirin, 2/153 (1.3%) chose aspirin plus clopidogrel, while one respondent (0.6%) chose aspirin plus ticagrelor. For this patient group, 19/153 (12.4%) respondents would not consider restarting any form of ATT.

For patients with AF who had an ICH while on VKA, the preferred choice of ATT post-ICH was apixaban (88/153, 57.5%), followed by one of the other NOACs, dabigatran (22/153, 14.4%), rivaroxaban (17/153, 11.1%), and edoxaban (8/153, 5.2%). Restarting VKA with a lower INR range of 2.0–2.5 was the preferred option for 5/153 (3.3%) respondents, while restarting VKA with a traditional target INR range of 2.0–3.0 was the preferred option for only 2/153 (1.3%) respondents. No respondents chose to start antiplatelet therapy for patients who sustained an ICH while on VKA.

**Reasons for not restarting or commencing oral anticoagulation**

Concern for recurrent ICH was the main reason for not restarting or commencing OAC in patients with AF post-ICH (118/146, 80.8%) (Figure 5), in addition to other types of bleeding, such as a history of major bleeding (82/146, 56.2%) and multiple micro-bleeds (67/146, 45.8%).

**Figure 3** First choice of antithrombotic therapy for a patient with AF who sustained an ICH on VKA or NOAC. ATT, antithrombotic therapy; INR, international normalized ratio; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin-K antagonist.
45.9%). Half (74/146, 50.7%) of the respondents selected suspected CAA as a reason not to prescribe OAC post-ICH. Only 39% (57/146) would not commence or restart OAC in patients with a high risk of bleeding (HAS-BLED score ≥3). Other common reasons for not restarting or commencing OAC post-ICH were poor patient adherence with medication or follow-up appointments (88/146, 60.3%), reduced life expectancy (84/146, 57.5%), and severe multi-morbidity (76/146, 52.1%). Dementia and increased risk of falls were reasons for not restarting OAC for 54/146 (37%) and 66/146 (45.2%) of participants, respectively. Very few respondents considered type of AF (8/146, 5.5%) or symptomatic AF in older patients (>75 years) (13/146, 9.9%) among their reasons for not restarting or commencing OAC in ICH-survivors with AF.

Timing of restarting or commencing oral anticoagulation

When considering the timing of restarting or commencing OAC in patients with AF and ICH, the responses were highly variable (Figure 6). Most (56/153, 36.6%) respondents would consider restarting some type of OAC >30 days post-ICH onset, 37/153 (24.2%) between days 15 and 30 post-event, and 25/153 (16.3%) within the first 10–14 days post-ICH. Fewer than 5% of respondents (7/153, 4.6%) would consider restarting or commencing OAC prior to hospital discharge, while 15/153 (9.8%) would not consider restarting OAC.

Alternatives to oral anticoagulation for stroke prevention in patients with atrial fibrillation post-intracerebral haemorrhage

In patients who were unable or unwilling to take OAC, 107/146 (73.3%) respondents preferred LAAO as their first-choice stroke prevention strategy. Single antiplatelet therapy was favoured as first choice by only 14/146 (9.6%) and dual antiplatelet therapy by 11/146 (7.5%) respondents. Around 10% of respondents would opt for no
stroke prevention therapy among patients unable or unwilling to take OAC.

**Barriers to restarting or commencing oral anticoagulation**

For the overwhelming majority of respondents (135/145, 93%), recurrent ICH was the main barrier to prescribing OAC to patients with AF who had survived an ICH (Figure 7), followed by concerns about major bleeding (91/145, 63%), risk of falls (70/145, 48%), concerns about patient adherence to medication or follow-up appointments (63/145, 43%), and patients’ understanding of medication choice (40/145, 28%). Lack of clinical guidelines and paucity of clinical evidence were also cited as barriers to prescribing OAC to patients with AF and ICH [30/145 (21%) and 40/145 (28%), respectively].

**Factors that could improve or support physicians’ decision-making**

International or national clinical guidelines were reported as the most important tool for making decisions about ATT for patients with AF post-ICH (123/145, 84.8%) (Supplementary material online, Figure S1), with nearly half of respondents (72/145, 49.7%) desiring more robust clinical evidence. A similar percentage of respondents (68/145, 46.9%) reported that greater multidisciplinary input would aid them in their decision-making process.

Education, both patient and physician, was identified as a tool to aid physicians’ decision-making regarding ATT for patients with AF and ICH. Improved patient education about their condition and risk factors for recurrent bleeding (65/145, 44.8%) and treatment options (54/145, 37.2%) were cited as beneficial and almost one-third of respondents (43/145, 29.7%) said that improved physician education about treatment options would be advantageous.

**Patient education tools utilized by physicians**

Most respondents (120/145, 82.8%) reported providing informal education at the bedside or during clinic appointment (101/145, 69.7%), with written information utilized by only one-third (48/145, 33%) of respondents. Some respondents referred patients to a specialist.
support group (30/145, 20.7%), signposted them to online sources of information (24/145, 16.5%), or engaged a specialist nurse to provide patients with information (25/145, 17.2%).

Scenario-based questions
Five scenario-based questions were presented (Box 1) and respondents were asked to state their first choice of ATT or alternative stroke prevention strategy. For all scenarios, NOAC were preferred to VKA and apixaban was the most popular NOAC. In Scenario 4, which referred to a patient with reduced renal function (CrCl of 47 mL/min), most respondents (47/138, 34.1%) chose the reduced dose of apixaban 2.5 mg bid, although 19/138 (13.8%) respondents chose the standard dose of apixaban 5 mg bid.

Dabigatran was the second most popular NOAC, especially in Scenario 2, which referred to a 57-year-old female patient; with 18/138 (13%) participants choosing dabigatran 150 mg bid and 6/138 (4.3%) choosing dabigatran 110 mg bid. Edoxaban was the least popular choice amongst all the NOACs. Antiplatelet therapy was not a popular choice for any of the scenarios.

Left atrial appendage occlusion procedure was the preferred stroke prevention therapy for a patient who sustained an ICH due to CAA (Scenario 3), with 69/134 (59.5%) participants selecting this option. Left atrial appendage occlusion procedure was also a popular treatment choice for Scenario 5, (57-year-old female patient with HAS-BLED = 4), chosen by 49/138 (29.7%) participants.

No stroke prevention therapy was chosen by 17/134 (12.7%) respondents for patients who sustain an ICH due to CAA (Scenario 3). For all other scenarios, no stroke prevention therapy was not a popular choice, with <4% choosing this option.

Discussion
Respondents were more likely to prescribe NOAC rather than VKA for stroke prevention for patients with AF comorbid with ICH. Antiplatelet therapy was not a popular choice for stroke prevention amongst survey participants, in-line with current clinical guidelines.10 Left atrial appendage occlusion procedure was the stroke prevention strategy of choice for patients who sustain an ICH due to CAA.

Non-VKA oral anticoagulants are recommenced as first-line OAC treatment by the European Society of Cardiology (ESC) and the American Heart Association (AHA) guidelines for the treatment of AF.11,12 Aspirin therapy is less effective in preventing stroke in patients with AF as compared to OAC,13 nor does aspirin reduce the risk of bleeding as compared to VKA.14 Clinical guidelines suggest that OAC rather than antiplatelet therapy should be the stroke prevention treatment of choice for patients with AF.10

Left atrial appendage occlusion procedure was a popular choice, especially in patients with increased bleeding risk or patients who survived an ICH while on OAC or among patients with CAA who are at risk of repeat ICH and ischaemic stroke.15 Most participants in this survey were cardiologists and electrophysiologists, which may help explain the popularity of LAAO procedure. Nonetheless, concerns about the safety and efficacy of LAAO procedures remain16 and patients still require antiplatelet therapy post LAAO procedure.16,17

Recurrence ICH and risk of bleeding were the major barriers to commencing or restarting OAC. These concerns mirror those expressed by neurosurgeons who reported that the risk of recurrent ICH was the main contraindication to restarting OAC therapy.18 The results of the present survey reflected this, as respondents predominantly considered the severity, type, and aetiology of the patient’s ICH, and the patient’s CHA2DS2-VASc score when deciding on post-ICH ATT.

The survey also showed that patients’ age, history of falls, and functional status were important considerations in post-ICH ATT decisions. Patients with AF who are older, have reduced functional status or dementia are less likely to receive OAC therapy.19–23 Prescribers report being concerned about bleeding due to falls and about patients’ ability to adhere to medication.22 However, a patient would have to fall nearly 300 times before the risk of a major bleed on warfarin would outweigh the benefits.23

Decision-making in antithrombotic therapy in patients with atrial fibrillation and intracerebral haemorrhage
Respondents felt that the lack of international or national clinical guidelines and paucity of RCTs data on post-ICH ATT management affected decision-making. Nonetheless, several RCTs addressing ATT in this patient group are ongoing. These include APACHE-AF (NCT025565693), ASPIRE (NCT03907046), PRESTIGE-AF (NCT03996772), NASPAM-ICH (NCT02998905), STATICH (NCT03186729), and SoSTAR (NCT 03186729).

Multidisciplinary working was also recognized as helpful by almost half of the survey participants, which is in-line with current European clinical guidelines.11 Integrated care of patients with AF has been shown to reduce all-cause mortality and cardiovascular hospitalizations.24 Use of the Atrial Fibrillation Better Care (ABC) Pathway, which promotes a streamlined approach to AF care, has been shown to reduce all-cause mortality when used in patients with AF who have a high frailty risk and to reduce healthcare costs associated with cardiovascular events in patients with AF.25,26

Patient involvement in decision-making
Almost 90% of respondents considered patient preference when deciding whether to restart or commence ATT. However, respondents also felt that better patient knowledge of their conditions and treatment options would aid decision-making. Patients with AF often lack knowledge about their condition,27,28 as do patients with stroke.29,30 Almost all survey respondents stated that they provide some form of informal education to their patients. However, patients with AF who participated in an enhanced education programme showed better understanding of their condition vs. usual care.31 Anticoagulation control and uptake of OAC also improved post-structured education interventions.31,33

Limitations
The response rate was low, with only 163 participants overall. Participation also varied by question, meaning that not every participant answered every question. The low response rate limits the ability of the survey to provide a comprehensive snapshot of current practice regarding ATT for patients with AF and ICH and limits generalizability. The survey responses came mainly from cardiologists and electrophysiologists, which reflects the membership of EHRA.
However, patients with AF who survive an ICH receive input from multiple other specialties and treatment patterns may differ by specialty and timing in the treatment pathway (acute vs. longer term).

Conclusions

This EHRA survey provides a snapshot of current practice regarding ATT for patients with AF post-ICH. Non-VKA oral anticoagulants are the treatment of choice, including for patients who experienced an ICH while on OAC; apixaban was the most popular NOAC. Left atrial appendage occlusion procedure was a popular choice in patients with increased bleeding risk, particularly CAA. Decision-making is complicated by concerns about major bleeding, patient's functional status, falls risk, and medication adherence. Concern for recurrent ICH was the main reason for not prescribing OAC. Ongoing RCTs will hopefully provide definitive evidence on safety and efficacy of ATT in AF patients post-ICH to inform clinical decision-making.

Supplementary material

Supplementary material is available at Europace online.

Acknowledgements

The production of this document is under the responsibility of the Scientific Initiatives Committee of the European Heart Rhythm Association: Tatjana S. Potpara (Chair), Radoslaw Lenarczyk (Co-Chair), Giulio Conte, Gheorghe Andrei Dan, Michal M. Farkowski, Malcolm Finlay, Estelle Gandjakhch, Konstantinos E. Iliodromitis, Kristine Jubele, Deirdre A. Lane, Eloi Marijon, Francisco Marin, Frits Prinzen, and Daniel Scherr. This work was also conducted in collaboration with the European Society of Cardiology (ESC) Council on Stroke.

Conflict of interest: EI, G.-A.D., KL, and RL declared none. D.A.L. received investigator-initiated educational grants from Bristol Myers Squibb (BMS) and Boehringer Ingelheim; been a speaker for Boehringer Ingelheim, Bayer, and BMS/Pfizer, and consulted for Boehringer Ingelheim, Bayer, BMS/Pfizer, and Daiichi-Sankyo; all outside the submitted work. W.D. received grants and personal fees from Amediq, Bayer, Boehringer Ingelheim, Lilly, Medtronic, Pfizer, Sanofi-Aventis, Sphingotec, Vifor Pharma, and ZS Pharma, all outside the submitted work. M.M.F. received speaker fees and travel grants from Pfizer and Boehringer Ingelheim. T.S.P. is a consultant for Bayer and Pfizer (no fees).

Data availability

Data are stored by European Society of Cardiology (ESC) and only ESC staff, European Heart Rhythm Association Scientific Initiatives Committee Chair and authors of the survey have access to the data. Data would be made available upon reasonable request to the senior author.

References


